HomeCompareACER vs SBUX

ACER vs SBUX: Dividend Comparison 2026

ACER yields 302.98% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACER wins by $1618.17M in total portfolio value
10 years
ACER
ACER
● Live price
302.98%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1618.34M
Annual income
$981,251,733.53
Full ACER calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — ACER vs SBUX

📍 ACER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACERSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACER + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACER pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACER
Annual income on $10K today (after 15% tax)
$25,753.67/yr
After 10yr DRIP, annual income (after tax)
$834,063,973.50/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, ACER beats the other by $834,003,507.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACER + SBUX for your $10,000?

ACER: 50%SBUX: 50%
100% SBUX50/50100% ACER
Portfolio after 10yr
$809.25M
Annual income
$490,661,435.00/yr
Blended yield
60.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

ACER
Analyst Ratings
1
Strong
3
Buy
4
Hold
Consensus: Hold
Altman Z
-29.9
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACER buys
0
SBUX buys
0
No recent congressional trades found for ACER or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACERSBUX
Forward yield302.98%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$1618.34M$167.0K
Annual income after 10y$981,251,733.53$71,136.45
Total dividends collected$1554.65M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: ACER vs SBUX ($10,000, DRIP)

YearACER PortfolioACER Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$40,998$30,298.44$11,121$420.68+$29.9KACER
2$159,961$116,092.41$12,548$648.40+$147.4KACER
3$594,475$423,317.38$14,440$1,013.98+$580.0KACER
4$2,106,378$1,470,289.30$17,068$1,617.30+$2.09MACER
5$7,122,619$4,868,794.58$20,912$2,649.52+$7.10MACER
6$23,007,746$15,386,544.17$26,875$4,499.29+$22.98MACER
7$71,068,926$46,450,637.66$36,771$8,014.12+$71.03MACER
8$210,139,057$134,095,305.48$54,542$15,197.11+$210.08MACER
9$595,407,325$370,558,534.30$89,602$31,242.49+$595.32MACER
10$1,618,337,571$981,251,733.53$167,011$71,136.45+$1618.17MACER

ACER vs SBUX: Complete Analysis 2026

ACERStock

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Full ACER Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this ACER vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACER vs SCHDACER vs JEPIACER vs OACER vs KOACER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.